Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

John J Kavanagh, Charles F Levenback, Pedro T Ramirez, Judith L Wolf, Carla L Moore, Marsha R Jones, Lisa Meng, Gail L Brown, Robert C Bast Jr, John J Kavanagh, Charles F Levenback, Pedro T Ramirez, Judith L Wolf, Carla L Moore, Marsha R Jones, Lisa Meng, Gail L Brown, Robert C Bast Jr

Abstract

Background: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m2 in combination with PLD at 50 mg/m2, intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS).

Results: Canfosfamide plus PLD combination therapy was administered at 960/50 mg/m2, respectively. Thirty-nine patients received a median number of 4 cycles (range 1.0-18.0). The ORR was 27.8% (95% CI, 14.2-45.2) with a disease stabilization rate of 80.6% (95% CI, 64.0-91.8) in the evaluable population. The CA-125 marker responses correlated with the radiological findings of complete response or partial response. The median PFS was 6.0 months (95% CI, 4.2-7.9) and median survival was 17.8 months. The combination was well tolerated. Myelosuppression was managed with dose reductions and growth factor support. Grade 3 febrile neutropenia was observed in 2 patients (5.1%). Non-hematologic adverse events occurred at the expected frequency and grade for each drug alone, with no unexpected or cumulative toxicities.

Conclusions: Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer. A randomized phase 3 study was conducted based on this supportive phase 2 study.

Trial registration: ClinicalTrials.gov NCT00052065.

Figures

Figure 1
Figure 1
Progression-free survival (PFS) in patents with platinum refractory or resistant epithelial ovarian cancer.
Figure 2
Figure 2
Survival in patents with platinum refractory or resistant epithelial ovarian cancer.

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA: A Cancer Journal for Clinicians. 2009;59(4):225–49. doi: 10.3322/caac.20006.
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59. doi: 10.1200/JCO.20.5.1248.
    1. Du Bois A, Quinn M, Thigpen T. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol. 2005;16(Suppl 8):viii7–viii12. doi: 10.1093/annonc/mdi961.
    1. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–16. doi: 10.1038/nrc1123.
    1. Thigpen T. Design Issues in Clinical Trials of Ovarian Carcinoma. FDA and the American Society of Clinical Oncology (ASCO), with co-sponsorship by the American Association for Cancer Research (AACR), public workshop on endpoints for ovarian cancer. 2006.
    1. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1–8. doi: 10.1016/j.ygyno.2004.07.011.
    1. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–22.
    1. Lyttle MH, Satyam A, Hocker MD. Glutathione-S-transferase activates novel alkylating agents. J Med Chem. 1994;37(10):1501–7. doi: 10.1021/jm00036a016.
    1. Satyam A, Hocker MD, Kane-Maguire KA, Morgan AS, Villar HO, Lyttle MH. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J Med Chem. 1996;39(8):1736–47. doi: 10.1021/jm950005k.
    1. Gate L, Tew KD. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets. 2001;5(4):477–89. doi: 10.1517/14728222.5.4.477.
    1. Montali JA, Wheatley JB, Schmidt DE Jr. Comparison of glutathione S-transferase levels in predicting the efficacy of a novel alkylating agent. Cell Pharmacol. 1995;2:241–7.
    1. Moscow JA, Fairchild CR, Madden MJ. Expression of anionic glutathione- S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 1989;49(6):1422–8.
    1. Tew KD, Monks A, Barone L. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute Drug Screening Program. Mol Pharmacol. 1996;50(1):149–59.
    1. Meng F, Brown GL, Keck JG. TLK286-induced activation of JNK-dependent apoptotic signaling pathway. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 29-November 2, 2001; Miami Beach. p. 67. Abstract #326.
    1. Meng F, Kim S, Brown GL. TLK286-induced activation of the stress response apoptotic signaling pathway. Proceedings of the Annual Meeting of the American Association for Cancer Research; April 6-10, 2002; San Francisco, California. p. 963. Abstract #4772.
    1. Morgan AS, Sanderson PE, Borch RF. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res. 1998;58(12):2568–75.
    1. Rosario LA, O'Brien ML, Henderson CJ, Wolf CR, Tew KD. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol. 2000;58(1):167–74.
    1. Townsend DM, Shen H, Staros AL, Gate L, Tew KD. Efficacy of a glutathione S-transferase p-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther. 2002;1(12):1089–95.
    1. Xu H, Namgoong S-Y, Roth E. Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells. Proceedings of the American Association for Cancer Research; July 11-14, 2003; Washington DC. p. 462. Abstract 2008.
    1. Kavanagh JJ, Gershenson DM, Choi H. Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005;15(4):593–600. doi: 10.1111/j.1525-1438.2005.00114.x.
    1. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16. doi: 10.1093/jnci/92.3.205.
    1. Ban N, Takahashi Y, Takayama T. Transfection of glutathione S-transferase (GST)-p antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 1996;56(15):3577–82.
    1. Kavanagh J, Kudelka A, Lewis L. Phase 1-2a study of TLK286 (Telcyta™, a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (>/= 3rd line) ovarian cancer. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 17-21, 2003; Boston, MA. p. 222. Abstract C155.
    1. NCI National Cancer Institute. Common Toxicity Criteria (CTC) DCTD, NCI, NIH, DHHS; 1999.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81. doi: 10.2307/2281868.
    1. Ozols RF, Rubin SC, Thomas G, Robboy S. In: Principles and Practice of Gynecologic Oncology. 2. Hoskins WJ, Perez CA, Young RC, editor. Philadelphia: Lippincott-Raven Publishers; 1997. Epithelial Ovarian Cancer; pp. 919–86.
    1. Kavanagh J, Kudelka A, Spriggs D. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer. Proceedings of the Biennial Meeting of the International Gynecologic Cancer Society; October 20-24, 2002; Seoul, Korea. p. 530. Abstract OV034.
    1. Izbicka E, Lawrence R, Cerna C, Von Hoff DD, Sanderson PE. Activity of TER286 against human tumor colony-forming units. Anticancer Drugs. 1997;8(4):345–8. doi: 10.1097/00001813-199704000-00006.
    1. Wang Z, Keck JG, Brown GL. TLK286, a novel glutathione analog prodrug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells. Proceedings of the American Association for Cancer Research; April 16-20, 2005; Anaheim, CA. pp. 351–2. Abstract 1500.
    1. Xu H, Grossman E, Namgoong S-Y. Enhanced antitumor activity of TLK286 in combination with oxaliplatin, carboplatin, doxorubicin, paclitaxel and docetaxel in human colorectal, ovarian and breast cancer cell lines. Proceedings of the American Association for Cancer Research; April 5-9, 2003; Toronto, Canada. pp. 390–1. Abstract 1722.
    1. Vergote I, Finkler N, Hall J. Randomized Phase 3 Study of Canfosfamide (C, TLK286) plus Pegylated Liposomal Doxorubicin (PLD) vs PLD as Second-line Therapy in Platinum (P) Refractory or Resistant Ovarian Cancer (OC) Proceedings of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL. p. 289s. Abstract 5552.
    1. Vergote I, Finkler N, del Campo J. Phase 3 Randomized Study of Canfosfamide (Telcyta, TLK286) versus Pegylated Liposomal Doxorubicin or Topotecan as Third-Line Therapy in Patients with Platinum Refractory or Resistant Ovarian Cancer. Eur J Cancer. 2009;45:2324–32. doi: 10.1016/j.ejca.2009.05.016.
    1. Rose P, Edwards R, Finkler N. Phase 3 study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC) Proceedings of the Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL. p. 281s. Abstract #LBA5529.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren